SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. Issue 12 (December 2021)

• Record Type: Journal Article
• Authors: Sun, Lova; Surya, Sanjna; Goodman, Noah G.; Le, Anh N.; Kelly, Gregory; Owoyemi, Olutosin; Desai, Heena; Zheng, Cathy; DeLuca, Shannon; Good, Madeline L.; Hussain, Jasmin; Jeffries, Seth D.; Kry, Yolanda R.; Kugler, Emily M.; Mansour, Maikel; Ndicu, John; Osei-Akoto, AnnaClaire; Prior, Timothy; Pundock, Stacy L.; Varughese, Lisa A.; Weaver, JoEllen; Doucette, Abigail; Dudek, Scott; Verma, Shefali Setia; Gouma, Sigrid; Weirick, Madison E.; McAllister, Christopher M.; Bange, Erin; Gabriel, Peter; Ritchie, Marylyn; Rader, Daniel J.; Vonderheide, Robert H.; Schuchter, Lynn M.; Verma, Anurag; Maillard, Ivan; Mamtani, Ronac; Hensley, Scott E.; Gross, Robert; Wileyto, E. Paul; Huang, Alexander C.; Maxwell, Kara N.; DeMichele, Angela;
• Is Part Of: JCO oncology practice. Volume 17:Issue 12(2021)
• Publication Date: 2021-12
• Subjects: Oncology -- Periodicals; Medical Oncology; Neoplasms; Oncology; Periodicals; 616.994
• DOI: 10.1200/OP.21.00113
• Languages: English
• ISSNs: 2688-1527

Abstract

Abstract : PURPOSE: Multiple studies have demonstrated the negative impact of cancer care delays during the COVID-19 pandemic, and transmission mitigation techniques are imperative for continued cancer care delivery. We aimed to gauge the effectiveness of these measures at the University of Pennsylvania. METHODS: We conducted a longitudinal study of SARS-CoV-2 antibody seropositivity and seroconversion in patients presenting to infusion centers for cancer-directed therapy between May 21, 2020, and October 8, 2020. Participants completed questionnaires and had up to five serial blood collections. RESULTS: Of 124 enrolled patients, only two (1.6%) had detectable SARS-CoV-2 antibodies on initial blood draw, and no initially seronegative patients developed newly detectable antibodies on subsequent blood draw(s), corresponding to a seroconversion rate of 0% (95% CI, 0.0 TO 4.1%) over 14.8 person-years of follow up, with a median of 13 health care visits per patient. CONCLUSION: These results suggest that patients with cancer receiving in-person care at a facility with aggressive mitigation efforts have an extremely low likelihood of COVID-19 infection.